Nanomaterials Trigger Functional Anti-Tumoral Responses in Primary Human Immune Cells
- PMID: 40652336
- DOI: 10.1002/advs.202505729
Nanomaterials Trigger Functional Anti-Tumoral Responses in Primary Human Immune Cells
Abstract
Targeting the immune system with nanoparticles (NPs) to deliver immunomodulatory molecules emerged as a solution to address intra-tumoral immunosuppression and enhance therapeutic response. While the potential of nanoimmunotherapies in reactivating immune cells has been evaluated in several preclinical studies, the impact of drug-free nanomaterials on the immune system remains unknown. Here, the molecular and functional response of human NK cells and pan T cells to a selection of five NPs that are commonly used in biomedical applications are characterized. After a pre-screen to evaluate the toxicity of these nanomaterials on immune cells, ultrasmall silica-based gadolinium (Si-Gd) NPs and poly(lactic-co-glycolic acid) (PLGA) NPs are selected for further investigation. Bulk RNA-sequencing and flow cytometry analysis showcase that PLGA NPs trigger a transcriptional priming toward activation in NK and pan T cells. While PLGA NPs improved NK cells anti-tumoral functions in a cytokines-deprived environment, Si-Gd NPs significantly impaired T cells activation as well as functional responses to a polyclonal antigenic stimulation. Altogether, PLGA NPs are identified as an attractive strategy for reactivating the immune system of cancer patients.
Keywords: immunotherapy; nanomaterial; proteogenomics.
© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbH.
References
-
- I. Mellman, G. Coukos, G. Dranoff, Nature 2011, 480, 480.
-
- J. Galon, D. Bruni, Nat. Rev. Drug Discov. 2019, 18, 197.
-
- L. Galluzzi, J. Humeau, A. Buqué, L. Zitvogel, G. Kroemer, Nat. Rev. Clin. Oncol. 2020, 17, 725.
-
- L. Galluzzi, M. J. Aryankalayil, C. N. Coleman, S. C. Formenti, Nat. Rev. Clin. Oncol. 2023, 20, 543.
-
- M. A. Fischbach, J. A. Bluestone, W. A. Lim, Sci. Transl. Med. 2013, 5, 179ps7.
Grants and funding
- ProFI FR2048/CNRS, the University of Strasbourg, the Agence National de la Recherche, the French Proteomics Infrastructure
- ANR-10-INBS-08-03/CNRS, the University of Strasbourg, the Agence National de la Recherche, the French Proteomics Infrastructure
- ANR-10-IDEX-0002/IdEx Unistra
- ANR-20-SFRI-0012/SFRI-STRAT'US
- 950101/HORIZON EUROPE European Research Council